WO2010114270A2 - 고발현 재조합 세포주의 선별 방법 - Google Patents
고발현 재조합 세포주의 선별 방법 Download PDFInfo
- Publication number
- WO2010114270A2 WO2010114270A2 PCT/KR2010/001912 KR2010001912W WO2010114270A2 WO 2010114270 A2 WO2010114270 A2 WO 2010114270A2 KR 2010001912 W KR2010001912 W KR 2010001912W WO 2010114270 A2 WO2010114270 A2 WO 2010114270A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- polya
- expression vector
- cell line
- vector
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Definitions
- the present invention relates to a method for selecting a highly expressed recombinant cell line, and more specifically, to (i) a gene expression cassette comprising a selection marker gene linked to inoperable polyA; And (ii) a method for selecting a highly expressed recombinant cell line using an expression vector comprising a gene expression cassette encoding a recombinant protein of interest linked to operably polyA.
- the target protein to be produced is inserted into the expression vector of the gene of the target protein, transduced into the cell line to produce the inserted expression vector and cultured in a large amount in a cell line prepared by a suitable method Obtained through separation and purification.
- Examples of industrially used methods for this purpose include methods using Chinese hamster ovary (CHO) dihydrofolate reductase (dhfr) (-), CHO K1, Baby Hamster Kidney (BHK), NS0, SP2 / 0, and human cell lines.
- CHO Chinese hamster ovary
- dhfr dihydrofolate reductase
- BHK Baby Hamster Kidney
- SP2 / 0, and human cell lines Ogata, et al., Appl. Microbiol. Biotechnol. , 1993, 38 (4), 520-525; Kratje, et al., Biotechnol.Prog ., 1994, 10 (4), 410-20; Peakman, et al., Hum.Antibodies Hybridomas, 1994, 5 (1-2), 65-74).
- the foreign gene is generally inserted by transduction into the desired cell line together with a selection marker gene (eg neomycin phosphotransferase).
- a selection marker gene eg neomycin phosphotransferase
- Foreign and selectable marker genes can be expressed by a single vector or by separate vectors that are simultaneously transduced. 2-3 days after transduction, when using neomycin phosphotransferase-gene, cells are transferred to media containing a selection agent such as G418 and cultured for several weeks under these selection conditions. Appearing resistant cells can then be isolated and examined for expression of the desired gene product. As a result of random, non-directional integration into the host cell genome, cell populations expressing foreign genes in completely different proportions are obtained.
- They may also include non-expressing cells in which selectable markers are expressed but do not express the gene of interest. Therefore, in order to identify cell clones with high expression of the desired foreign genes, it is necessary to examine and test a large number of clones, which is time-consuming and expensive.
- Gene amplification is a common task in animal cell cultures used to produce recombinant proteins, and gene amplification dramatically improves the relatively low productivity inherent in many mammalian cell lines.
- One widely used amplification technique is the dhfr family of gene amplification systems, which are very commonly used in dhfr deficient CHO cells.
- CHO cell lines deficient in dhfr are industrially preferred for the following reasons: (1) Posttranslational modification of proteins, ie, glycosylation or phosphorylation. More similar to human cells than other cell lines; (2) suspension culture as well as attachment culture is possible; (3) relatively high concentration cultures are possible compared to other cells in serum-free medium; (4) significantly lower target protein productivity compared to microorganisms using dhfr / MTX (methotrexate) gene amplification system; And (5) stability has been verified, making it easy to obtain permits from regulatory agencies such as FDA. For this reason, dhfr-deficient CHO cell lines are widely used industrially to produce recombinant cell lines producing target proteins.
- the gene encoding the target protein was transduced into a CHO cell line lacking dfhr, and then gradually increased and treated to a concentration of MTX, thereby producing the target protein.
- the process of increasing the concentration of MTX step by step for a long time and the number of cells to be selected in this process is less than 500 to 4000 groups, high productivity cell population Screening becomes labor intensive, time consuming and costly. Therefore, efforts to simplify this screening step have been attempted in various ways.
- an object of the present invention is to provide a method for screening a highly expressed recombinant cell line using an expression vector comprising a selectable marker gene linked to polyA inoperable.
- Another object of the present invention is to provide an expression vector used in the above screening method.
- Still another object of the present invention is to provide a eukaryotic host cell line transfected with the expression vector.
- the present invention (i) a gene expression cassette comprising a selectable marker gene linked to polyA inoperable; And (ii) a high expression recombinant cell line using an expression vector comprising a gene expression cassette encoding a target recombinant protein to which polyA is operably linked.
- the present invention also provides a gene expression cassette comprising (i) a selectable marker gene linked to inoperable polyA; And (ii) a gene expression cassette encoding a recombinant protein of interest to which polyA is operably linked.
- the present invention also provides a eukaryotic host cell line transduced with the expression vector.
- a selection marker gene is a marker gene linked to a gene of a target protein and inserted into an expression vector.
- the selection marker gene enables selection of cells in which the target gene is normally expressed.
- adding an inhibitor of a protein encoded by the selectable marker gene to the medium may increase the number of copies of the selectable marker gene or increase the number of copies of the gene of the target protein linked to the increased selectable marker gene. To cause it.
- Selection markers include dhfr gene, glutamine synthetase gene, neomycin phosphotransferase gene, hygromycin B phosphotransferase gene, puromycin-N-acetyltransfer Puromycin-N-acetyltransferase (pac) gene, or Streptoalloteichus hindustanus (Sh) ble gene.
- polyA is a signal that cleaves a specific site at the 3 'end of eukaryotic mRNA and introduces about 100 to 200 adenine nucleotide (polyA tail) sequences after translation into the cleaved 3' end, the polyadenylation signal. Sequence refers to the consensus sequence AATAAA and downstream located about 10 to 30 nucleotides upstream from the cleavage site, and several polyA signals such as tk polyA, SV40 late and early polyA or BGH polyA, are known.
- “Operably linked” means that one nucleic acid fragment is combined with another nucleic acid fragment so that its function or expression is affected by the other nucleic acid fragment. “Operably linked” is governed by a promoter sequence in which transcription of the gene sequence is operably linked, is governed by a translation control sequence in which translation of the gene sequence is operably linked, or post-translational processing of the gene sequence is activated A link between a gene sequence and a promoter or other regulatory or processing sequence, possibly governed by linked processing sequences. By “operably linked” is meant in the opposite sense to encompass not being operable due to artificial manipulation by methods such as cleavage, deletion, point mutations and amino acid replacement known to those skilled in the art.
- the polyA has a great effect on the transcription and stability of mRNA and becomes shorter with time and begins to degrade mRNA when it is shortened to some extent. Therefore, the study focused on polyA to develop a new screening method, focusing on the fact that the half-life of mRNA is much shorter than that of normal mRNA when polyA does not operate normally.
- a polyA linked to a selectable marker gene in an expression vector is inoperable and then transduced into a host cell and cultured under selection conditions where an inhibitor of the protein encoded by the selectable marker gene is present, Since a poorly functioning selection marker gene cannot stably produce mRNA, most of the cells will die under the selection conditions, and only those cells transfected with a large number of copies of the vector can survive. In this case, since the selection marker gene and the gene encoding the recombinant protein of interest are included together in the expression vector used for transduction, the gene encoding the target protein is also present in a large number of copies in proportion to the copy number of the selection marker gene. Done.
- the inventors of the present invention have a 3 'end of the dhfr gene, which is a selection marker gene on the pCT107 vector (see FIG. 1).
- the polyA was cleaved with a suitable restriction enzyme and manipulated so that it could not be operated. Compared.
- the number of candidate cells of the recombinant protein producing cell line in the experimental group was 7.6 times smaller per plate inoculated with growth cells compared to the control group, and the growth rate was (1/26264) :( 1/814815), 31 times lower (see Table 2).
- the experiment was performed using the system using the pac selection marker in CHO K1 cells.
- the dhfr transcription unit (promoter-dhfr-polyA) on the pCT112 vector was removed, and the experimental group (pCT130 vector) (see FIG. 7) and SV40 into which only the SV40 promoter and the pac gene were inserted.
- pCT129 vector a control vector
- the present invention has been completed by confirming that the screening method of the present invention is useful for reducing cost and time in selecting a highly efficient recombinant protein-producing cell line using various screening markers.
- the present invention provides an antibody comprising: (i) a gene expression cassette comprising a selectable marker gene linked to inoperable polyA; And (ii) a high expression recombinant cell line using an expression vector comprising a gene expression cassette encoding a target recombinant protein to which polyA is operably linked.
- the expression vector may be an expression vector comprising a gene expression cassette comprising a selection marker gene from which polyA has been removed, instead of a gene expression cassette comprising a selection marker gene linked to inoperable polyA of (i). .
- the present invention provides a gene expression cassette comprising (i) a selectable marker gene to which polyA is operably linked; And (ii) cutting the expression vector comprising a gene expression cassette encoding the recombinant protein of interest linked to polyA to be operable with a suitable restriction enzyme to linearize the expression vector such that polyA of (i) is inoperative.
- a method of screening for expressing recombinant cell lines is provided.
- the selection marker gene is a dhfr gene, glutamine synthetase gene, neomycin phosphotransferase gene, hygromycin B phosphotransferase gene, prouro Mycin-N-acetyltransferase (pac) gene, or Streptoalloteichus hindustanus (Sh) ble gene, but not limited to any of the selectable marker genes known to those skilled in the art. It can be used in the present invention.
- the target recombinant protein is preferably a monoclonal antibody, but is not limited thereto.
- the host cell is a human host cell including a eukaryotic host cell, preferably a CHO cell, a hybridoma cell, or an F2N cell, but is not limited thereto. Any cell line can be used in the present invention.
- the present invention also provides a gene expression cassette comprising (i) a selectable marker gene linked to inoperable polyA; And (ii) a gene expression cassette encoding a recombinant protein of interest to which polyA is operably linked.
- the expression vector may include a gene expression cassette including a selection marker gene from which polyA has been removed, instead of a gene expression cassette including a selection marker gene to which polyA of (i) is inoperatively linked.
- the expression vector may include multiple cloning sites for the introduction of the gene encoding the target protein, instead of the gene encoding the target recombinant protein operably linked to the polyA of (ii).
- the selectable marker gene is an amplifiable selectable marker gene, preferably a dhfr gene or a glutamine synthetase gene, but is not limited thereto.
- the selection marker gene is a neomycin phosphotransferase gene, a hygromycin B phosphotransferase gene, a pac gene, or a shble gene, but is not limited thereto.
- the target recombinant protein is preferably monoclonal antibody, but is not limited thereto.
- the present invention provides a eukaryotic host cell line transduced with the expression vector.
- the host cell is preferably an animal cell, in the embodiment of the present invention used a CHO cell line, but is not limited thereto, including hybridoma cells, or human host cells including F2N cells. Therefore, any cell line for recombinant protein production known to those skilled in the art can be used in the present invention.
- the transduction method is preferably used a method known to those skilled in the art.
- a high-productivity cell clone can be selected for a population of cells 10 times or more smaller than a conventional cell line selection method, and a conventional stepwise gene amplification strategy including several amplification steps while increasing the amount of MTX.
- a conventional stepwise gene amplification strategy including several amplification steps while increasing the amount of MTX.
- high-productivity cell clones can be screened, resulting in more efficient recombinant protein production by reducing the time spent developing cell lines and reducing the labor and cost of selecting high-productivity cell clones. It is possible.
- FIG. 1 is a cleavage map of a pCT107 expression vector, the restriction enzymes Pme I, Cla I and Rsr II shown on the map are designed to prevent pCT107 from activating the heavy chain gene, light chain gene and DHFR gene of the antibody encoded by the pCT107 expression vector. The site to cleave the vector is shown.
- FIG. 3 is a graph comparing titers showing the selection of cell clones with and without polyA linked to the dhfr gene at 96 well-plate scale:
- RsrII cut A linear pCT107 vector engineered to render polyA linked to the dhfr gene inoperable by treatment with Rsr II.
- RsrII cut A linear pCT107 vector engineered to render polyA linked to the dhfr gene inoperable by treatment with Rsr II.
- 5 is a graph comparing titers showing the selection of cell clones with and without polyA linked to the dhfr gene on a 6 well-plate scale:
- RsrII cut A linear pCT107 vector engineered to render polyA linked to the dhfr gene inoperable by treatment with Rsr II.
- FIG. 6 is a graph comparing the production of the control group and the experimental group in a batch culture state using a shake flask of six p-clone titers showing high titers according to the conditions with and without polyA:
- RsrII cut A linear pCT107 vector engineered to render polyA linked to the dhfr gene inoperable by treatment with Rsr II.
- FIG. 7 is a schematic diagram of the expression vector cloning process of the pCT130 vector.
- FIG. 8 is a schematic of the expression vector cloning process of the pCT129 vector.
- pCT129 (with polyA): a control having polyA activity
- pCT129 (with polyA): a control having polyA activity
- FIG. 11 is a graph comparing the production of the control and experimental groups at the 6 well-plate scale:
- pCT129 (with polyA): a control having polyA activity
- Figure 13 is a graph comparing the production of the control group and the experimental group in batch culture using a shake flask.
- Example 1 Derivation of inoperable polyA
- pCT107 vector As a first step to investigate the expression level of the gene according to the presence or absence of polyA, three transcription units in the IgG antibody expression vector pCT107 vector (Fig. 1), the dhfr gene, the heavy chain gene and the light chain gene
- the pCT107 vector was cut using Rsr II, Pme I and Cla I restriction enzymes, respectively, to render the polyA operably linked to the 3 ′ end of the.
- the restriction enzymes Rsr II, Pme I, and Cla I linearize the IgG antibody expression vector by specifically recognizing and cleaving a specific sequence existing between the 3 'end of the dhfr gene, the heavy chain gene and the light chain gene, corresponding polyA. linearization).
- the restriction enzyme treatment method is as follows. Three tubes were prepared and each tube was prepared with (i) 30 ⁇ g pCT107 vector DNA and Rsr II (R0501S, NEB) 10 U, (ii) 30 ⁇ g pCT107 vector DNA and Pme I (R0560S, NEB) 10 U, and (iii ) 30 ⁇ g of pCT107 vector DNA and 10 U of Cla I (R1097S, NEB) were mixed and treated at 37 ° C. for 4 hours. Next, 0.1 times volume of NaOAC and 3 times volume of 100% ethanol (EtOH) were added to each tube and stirred, and the mixture was left at -70 ° C for 30 minutes to precipitate DNA pellets.
- EtOH 100% ethanol
- the linearized vector according to Example 1 was transfected into CHO DG44 cells in equal amounts. The transduction was performed to the control group and the experimental group as shown in Table 1 below:
- Control group Circular pCT107 Vector Not Treated with Restriction Enzyme Experimental group
- B Linear pCT107 vector engineered to inactivate polyA linked to dhfr gene by treatment with Rsr II Experimental group
- C R-linear pCT107 vector engineered with Pme I to inactivate polyA linked to dhfr gene
- D Linear pCT107 vector engineered with Cla I to inactivate polyA linked to dhfr gene
- the transduction method is as follows. CHO DG44 cells were seeded at 0.5 ⁇ 10 6 cells / well in a 6- well plate using MEM ⁇ medium (1140076, Invitrogen) containing 10% FBS (12105, Sigma), followed by FBS 24 hours later. Was replaced with MEM ⁇ medium. After 30 minutes, in each well, 2.5 ⁇ g of vector DNA of control (A), experimental group (B), experimental group (C) and experimental group (D) and 500 ⁇ l of Opti-SFM medium (12309-050, Invitrogen) were added well. After mixing, 6.25 ⁇ l of LTX (15338-100, Invitrogen) was added and stirred well using a vortex mixer. After the mixture was allowed to stand at room temperature for 30 minutes, 500 ⁇ l was added to each well, and after 4 hours, the mixture was replaced with MEM ⁇ medium containing serum.
- MEM ⁇ medium 1140076, Invitrogen
- ELISA was performed three days after the transduction.
- Goat's anti-human immunoglobulin G (Fc ⁇ ) (109-006-098, Jackson ImmunoReserarch) was adsorbed onto 96-well microtiter plates (449824, Nunc). The plates were blocked by treatment with phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA) and serially diluted samples were added to each well of the plate. After standing for 2 hours at room temperature, it was detected with a peroxidase-labeled goat anti-human ⁇ antibody (I1514, Sigma).
- PBS phosphate buffered saline
- BSA bovine serum albumin
- TMB tetramethyl benzidine
- human IgG1 kappa purified myeloma plasma A7164, Sigma
- the concentration was measured by reading the absorbance at 450/650 nm using a plate reader (Spectramax plus 384, Molecular Device).
- the pCT107 vector was treated with Rsr II restriction enzymes (R0501, NEB) under the same treatment conditions as in Example 1 (Experimental Group (E)). And transduced into CHO DG44 cell line.
- a pCT107 vector (control (A)) not treated with a restriction enzyme was used as a control. Transduction was performed in the same manner as in Example 1. The expression levels of IgG antibodies measured 3 days after the vectors of the control group (A) and the test group (E) were introduced into the cell line were 3.9 ⁇ g / ml and 3.8 ⁇ g / ml, respectively.
- control (A) and experimental (E) cells were transferred to 96-well-plates, respectively, containing 2% fetal bovine serum (FBS) and 100 nM MTX (813630, Bedford Labs). Culture was performed using SFM4CHO TM medium (SH30549.02, HyClone). Inoculation was inoculated in 0.5 x 10 6 cells / 96 well-plate for the control group (A) and 2 x 10 6 cells / 96 well-plate for the experimental group (E).
- the wells showing the high titer were selected from the wells with the cells growing.
- 157 wells were selected from 514 wells in the control group (A) and 54 in the experimental group (E). 28 wells were selected from the wells.
- the cells in the selected wells were transferred to 24-well-plates and the culture scale was increased to increase the culture scale.
- the cell groups showing high titers in the 24-well-plates were transferred to the control group (A) and the experimental group (E). Six were selected and inoculated in 6-well-plates and cultured.
- the six cell groups of the selected control group (A) and the experimental group (E) were named as p-clone, inoculated into a Erlenmeyer flask using a medium without FBS and MTX, and cultured under agitation conditions with the control group (A) and The productivity of the experimental group (E) was compared.
- the cell lines used in the experiment were CHO K1 and F2N78 (human cell line), and each cell line was cultured in CD Opti CHO medium (12681, Invitrogen) and EX-CELL 293 serum-free medium (14571c, Sigma). The same medium was used in the example. Inoculation concentrations of cells were added to each well of 6 well-plates at 5 ⁇ 10 4 cells / ml and 15 ⁇ 10 4 cells / ml, which concentration per plate was based on the actual 96 well-plate standard. (20 ml) 1 ⁇ 10 6 ⁇ 10 6 cells sepogwa 3 corresponds to the concentration.
- the concentrations of 1 ⁇ 10 6 cells and 3 ⁇ 10 6 cells in 96 well-plates are the cell concentrations used in the selection method using a selection marker that lacked polyA in Example 6.
- Three concentrations of drug per cell line were applied and half of the culture medium (2.5 mL) was removed in each well every 3 days and the same amount of fresh medium was added.
- the types and details of the treated drugs are indicated in Table 4 below.
- the fresh medium always contained the drug at the indicated concentration.
- the screening method using the dhfr selection marker gene linked to polyA inoperability was found to be very efficient in terms of cost and time saving for high-productivity cell clone selection in CHO DG44 cell line.
- this screening method is applied to other screening markers and other cell lines other than the dhfr gene and the CHO DG44 cell line, this time, the screening method using the pac selection marker gene which is completely depleted of polyA was applied to the CHO K1 cell line. Reviewed.
- the dhfr transcription unit (promoter-dhfr gene-polyA) is completely removed from the immunoglobulin expression vector (pCT112 vector), and the promoter-pac gene or promoter- is removed in order to completely remove the function of polyA.
- pCT130 vector and pCT129 vector in which the pac gene-polyA was inserted were constructed (FIGS. 7 and 8). The vector production method is as follows.
- the cloned pPRU vector was selected by using the Pvu II and BamH I (R0136S, NEB) restriction enzymes to insert the SV40 promoter, pac gene, and polyA at the position where the dhfr transcription unit of the pCT112 vector was removed.
- PCT129 vector (FIG. 8) was produced.
- CHO K1 cell lines were transfected with pCT129 vector and pCT130 vector, and two days later, 96 well-plates were inoculated respectively using a medium to which various concentrations of puromycin were added as shown in Table 5 below.
- the medium used at this time is CD OptiCHO medium and FBS was not added.
- the inoculation concentration of 0.3 ⁇ 10 6 cells / plate and the selection conditions of 6 ⁇ g / ml puromycin were appropriate.
- 3 ⁇ 10 6 Inoculation concentrations of cells / plates and selection conditions using 6 ⁇ g / ml puromycin were appropriate.
- a number of transfection experiments were performed to compare the expression levels of immunoglobulins by selecting similar numbers of p-clone from the group with the polyA (control) and the group without the selection marker (control group).
- the high-productivity p-clone 129-4 and 130-35 were selected from each group for limiting dilution cloning (LDC).
- LDC limiting dilution cloning
- clones derived from the pCT130 vector had a higher yield than clones derived from the pCT129 vector (the yield of 7-18 ⁇ g / ml / 3 days). It is about twice as high. It can be seen that clones with higher productivity can be produced from vectors without polyA of the selection marker. In addition, in stationary culture conditions using shake flasks, which can examine productivity in a more practical manner, as shown in FIG. 13, clones derived from the pCT130 vector (experimental group) without polyA of the selection marker had a productivity of 62-72 ⁇ g / ml.
- clones derived from the pCT129 vector (control) with polyA of the selection marker showed a productivity of 2-10 ⁇ g / ml.
- clones derived from the pCT130 vector (experimental group) showed a six-fold productivity. This remarkable difference may be attributed to the fact that clones derived from the pCT129 vector (control) are likely to be either inhibited by the expression of the IgG gene or readily deleted in the absence of selection conditions.
- the present invention can obtain a cell line with a high antibody expression amount compared to the cell line transduced with the expression vector containing the polyA of the selection marker, the cell line transduced with the expression vector without the polyA of the selection marker. It can be seen that. Therefore, the screening method according to the present invention can reduce the time for screening high-productivity cell clones as compared to conventional stepwise gene amplification strategies that include several amplification steps while increasing the amount of MTX, and thus human / physical development. This is a way to reduce costs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
대조군(A) | 제한효소로 처리하지 않은 환형 pCT107 벡터 |
실험군(B) | Rsr II로 처리하여 dhfr 유전자에 연결된 polyA가 작동 불가능하도록 조작된 선형 pCT107 벡터 |
실험군(C) | Pme I으로 처리하여 dhfr 유전자에 연결된 polyA가 작동 불가능하도록 조작된 R선형 pCT107 벡터 |
실험군(D) | Cla I으로 처리하여 dhfr 유전자에 연결된 polyA가 작동 불가능하도록 조작된 선형 pCT107 벡터 |
대조군(A) | 실험군(E) | 대조군(A)/실험군(E) | |
접종 플레이트 수 | 27 | 22 | - |
총 웰 수 | 2,592 | 2,112 | - |
양성 성장 반응 보이는 웰 수 | 514 (19.8%) | 54 (2.5%) | 9.5 |
양성 성장 반응 보이는 웰 수/접종 플레이트 수 | 19.8 | 2.6 | 7.8 |
접종 농도 | 0.5x106 세포/플레이트 | 2.0x106 세포/플레이트 | - |
총 접종 세포수 | 1.35x107 세포 | 4.4x107 세포 | - |
양성 성장 세포 비율 | 1/26,264 세포 | 1/814,815 세포 | 31 |
Blasticidin(㎍/㎖) | G418(㎍/㎖) | HygB(㎍/㎖) | puromycin(㎍/㎖) | Zeocin(㎍/㎖) | |
선별마커 유전자 약자 | Bsd | neo | Hyg | pag | Zeo |
CHO K1 | 102040 | 4008001200 | 2505001000 | 4816 | 2505001000 |
F2N | 102040 | 적용 불가* | 200400800 | 248 | 200400800 |
선별 드럭 | 제조사 | 선별마커 유전자 | Cat # |
G418 또는 Geneticinⓡ(Invitrogen brand name) | Invitrogen | G418 | 10131-035 |
Puromycin | Invitrogen | pac | A11138-03 |
Blasticidin SHCl | Invitrogen | bsd, bsr | A11139-03 |
ZeocinTM | Invitrogen | sh ble(zeor) | R250-01 |
Hygromycin B(mycophenolic acid) | Invitrogen | hyg, hph | 10678-010 |
pCT129 벡터(대조군:polyA 있는 pac 유전자 사용) | pCT130 벡터(실험군:polyA 없는 pac 유전자 사용) | ||
Seeding density(×106 cells/plate) | Puromycin(㎍/㎖) | Seeding density(×106 cells/plate) | Puromycin(㎍/㎖) |
0.1 | 6 | 1 | 10 |
8 | 3 | 6 | |
0.3 | 6 | 8 | |
10 |
Claims (16)
- (i) 폴리아데닐화 시그널(polyA)이 작동 불가능하도록 연결된 선별 마커 유전자를 포함하는 유전자 발현 카세트; 및 (ii) polyA가 작동 가능하도록 연결된 목적 재조합 단백질을 암호화하는 유전자 발현 카세트를 포함하는 발현 벡터를 이용한 고발현 재조합 세포주의 선별 방법.
- 제1항에 있어서, 상기 발현 벡터가 (i)의 polyA가 작동 불가능하도록 연결된 선별 마커 유전자를 포함하는 유전자 발현 카세트 대신, polyA를 제거한 선별 마커 유전자를 포함하는 유전자 발현 카세트를 포함하는 것을 특징으로 하는 발현 벡터인 것을 특징으로 하는 고발현 재조합 세포주의 선별 방법.
- (i) polyA가 작동 가능하도록 연결된 선별 마커 유전자를 포함하는 유전자 발현 카세트; 및 (ii) polyA가 작동 가능하도록 연결된 목적 재조합 단백질을 암호화하는 유전자 발현 카세트를 포함하는 발현 벡터를 적당한 제한 효소로 절단하여 (i)의 polyA가 작동하지 않도록 발현 벡터를 선형화시키는 단계를 포함하는 고발현 재조합 세포주의 선별 방법.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 선별 마커 유전자가 dhfr(dihydrofolate reductase) 유전자, 글루타민 신테타제(glutamine synthetase) 유전자, 네오마이신 포스포트랜스퍼라제(neomycine phosphotransferase) 유전자, 하이그로마이신 B 포스포트랜스퍼라제(hygromycin B phosphotransferase) 유전자, 푸로마이신-N-아세틸트랜스퍼라제(puromycin-N-acetyltransferase; pac) 유전자, 또는 스트렙도알로데이커스 힌더스터너스(Streptoalloteichus hindustanus: Sh) ble 유전자인 것을 특징으로 하는 고발현 재조합 세포주의 선별 방법.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 목적 재조합 단백질이 모노클로날 항체인 것을 특징으로 하는 고발현 재조합 세포주의 선별 방법.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 숙주 세포가 진핵 숙주 세포인 것을 특징으로 하는 고발현 재조합 세포주의 선별 방법.
- 제6항에 있어서, 상기 진핵 숙주 세포가 CHO 세포, 하이브리도마 세포, 또는 F2N 세포를 포함하는 인간 숙주 세포인 것을 특징으로 하는 고발현 재조합 세포주의 선별 방법.
- (i) polyA가 작동 불가능하도록 연결된 선별 마커 유전자를 포함하는 유전자 발현 카세트; 및 (ii) polyA가 작동 가능하도록 연결된 목적 재조합 단백질을 암호화하는 유전자 발현 카세트를 포함하는 발현 벡터.
- 제8항에 있어서, (i)의 polyA가 작동 불가능하도록 연결된 선별 마커 유전자를 포함하는 유전자 발현 카세트 대신, polyA를 제거한 선별 마커 유전자를 포함하는 유전자 발현 카세트를 포함하는 것을 특징으로 하는 발현 벡터.
- 제8항에 있어서, 상기 발현 벡터가 (ii)의 polyA가 작동 가능하도록 연결된 목적 재조합 단백질을 암호화하는 유전자 대신, 목적 단백질을 암호화하는 유전자의 도입을 위한 다중 클로닝 부위를 포함하는 것을 특징으로 하는 발현 벡터.
- 제8항 내지 제10항 중 어느 한 항에 있어서, 상기 선별 마커 유전자가 증폭 가능한 선별 마커 유전자인 것을 특징으로 하는 발현 벡터.
- 제11항에 있어서, 상기 증폭 가능한 선별 마커 유전자가 dhfr 유전자 또는 글루타민 신테타제 유전자인 것을 특징으로 하는 발현 벡터.
- 제8항 내지 제10항 중 어느 한 항에 있어서, 상기 선별 마커 유전자가 글루타민 신테타제 유전자, 네오마이신 포스포트랜스퍼라제 유전자, 하이그로마이신 B 포스포트랜스퍼라제 유전자, pac 유전자, Sh ble 유전자인 것을 특징으로 하는 발현 벡터.
- 제8항 내지 제10항 중 어느 한 항에 있어서, 상기 목적 재조합 단백질이 모노클로날 항체인 것을 특징으로 하는 발현 벡터.
- 제8항 내지 제10항 중 어느 한 항에 따른 발현 벡터로 형질 도입된 진핵 숙주 세포.
- 제15항에 있어서, 상기 진핵 숙주 세포가 CHO 세포, 하이브리도마 세포, 또는 F2N 세포를 포함하는 인간 숙주 세포인 것을 특징으로 하는 진핵 숙주 세포.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10758995.4A EP2418282B1 (en) | 2009-03-31 | 2010-03-30 | Method for selecting a high expression recombinant cell line |
US13/255,004 US9309519B2 (en) | 2009-03-31 | 2010-03-30 | Method for selecting a high expression recombinant cell line |
CN201080013851.XA CN102365364B (zh) | 2009-03-31 | 2010-03-30 | 用于选择高效表达重组细胞系的方法 |
JP2012503316A JP5899109B2 (ja) | 2009-03-31 | 2010-03-30 | 高発現組換え細胞系の選択方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0027871 | 2009-03-31 | ||
KR20090027871 | 2009-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010114270A2 true WO2010114270A2 (ko) | 2010-10-07 |
WO2010114270A3 WO2010114270A3 (ko) | 2011-02-17 |
Family
ID=42828829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/001912 WO2010114270A2 (ko) | 2009-03-31 | 2010-03-30 | 고발현 재조합 세포주의 선별 방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9309519B2 (ko) |
EP (1) | EP2418282B1 (ko) |
JP (1) | JP5899109B2 (ko) |
KR (1) | KR101160048B1 (ko) |
CN (1) | CN102365364B (ko) |
WO (1) | WO2010114270A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9309519B2 (en) | 2009-03-31 | 2016-04-12 | Celltrion Inc. | Method for selecting a high expression recombinant cell line |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103468742B (zh) * | 2012-11-22 | 2015-04-29 | 苏州康宁杰瑞生物科技有限公司 | GS-DHFRmut双基因筛选表达载体、制备方法及应用 |
IT201700099467A1 (it) | 2017-09-05 | 2019-03-05 | Cottlab Ltd | Mietitrice robotica semovente per la raccolta selettiva di colture agricole in file di alta qualità |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE669986T1 (de) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
ES2252070T3 (es) | 1999-10-13 | 2006-05-16 | Immunex Corporation | Vectores y procedimientos para la expresion de proteinas recombinantes. |
KR101160048B1 (ko) | 2009-03-31 | 2012-06-26 | (주)셀트리온 | 목적 단백질 고발현 세포주의 선별 방법 |
-
2010
- 2010-03-30 KR KR1020100028222A patent/KR101160048B1/ko active IP Right Grant
- 2010-03-30 CN CN201080013851.XA patent/CN102365364B/zh active Active
- 2010-03-30 JP JP2012503316A patent/JP5899109B2/ja active Active
- 2010-03-30 WO PCT/KR2010/001912 patent/WO2010114270A2/ko active Application Filing
- 2010-03-30 US US13/255,004 patent/US9309519B2/en active Active
- 2010-03-30 EP EP10758995.4A patent/EP2418282B1/en active Active
Non-Patent Citations (1)
Title |
---|
See references of EP2418282A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9309519B2 (en) | 2009-03-31 | 2016-04-12 | Celltrion Inc. | Method for selecting a high expression recombinant cell line |
Also Published As
Publication number | Publication date |
---|---|
JP5899109B2 (ja) | 2016-04-06 |
KR101160048B1 (ko) | 2012-06-26 |
EP2418282A4 (en) | 2013-02-06 |
US20120009682A1 (en) | 2012-01-12 |
CN102365364B (zh) | 2015-01-21 |
EP2418282A2 (en) | 2012-02-15 |
KR20100109465A (ko) | 2010-10-08 |
US9309519B2 (en) | 2016-04-12 |
JP2012521779A (ja) | 2012-09-20 |
WO2010114270A3 (ko) | 2011-02-17 |
EP2418282B1 (en) | 2017-05-10 |
CN102365364A (zh) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130330819A1 (en) | Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells | |
EP1137808B1 (en) | Methods for making recombinant cells | |
Zboray et al. | Heterologous protein production using euchromatin-containing expression vectors in mammalian cells | |
KR100627753B1 (ko) | 포유동물의 유전자 발현을 위한 인간 하이브리드 숙주 세포 | |
CN1693467A (zh) | 快速构建目标基因高表达的哺乳动物细胞株的体系和方法 | |
Zhu et al. | New mammalian expression systems | |
Malm et al. | Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins | |
WO2010114270A2 (ko) | 고발현 재조합 세포주의 선별 방법 | |
Baranyi et al. | Rapid generation of stable cell lines expressing high levels of erythropoietin, factor VIII, and an antihuman CD20 antibody using lentiviral vectors | |
US20230340542A1 (en) | Platform for developing stable mammalian cell lines | |
US20110281301A1 (en) | The secretory capacity in host cells | |
EP2274418B1 (en) | Human host cell for producing recombinant proteins with high quality and quantity | |
US20230295666A1 (en) | Super-enchancers for recombinant gene expression in cho cells | |
WO2021125913A1 (ko) | 목적 단백질의 고발현을 위한 인트론을 포함하는 발현 카세트 및 이의 이용 | |
US20210002646A1 (en) | Dnmt3b gene-deficient cho cell line, preparation and applications thereof and recombinant protein expression system using the same | |
EP1144611A2 (en) | Method for recombinant protein production in mammalian cells comprising co-expression with fetuin | |
KR102256749B1 (ko) | 고발현 세포주 확립방법 | |
US20170233695A1 (en) | Cell Culture Media Composition and Methods of Producing Thereof | |
Brown et al. | Expression Systems for Recombinant Biopharmaceutical Production by Mammalian Cells in Culture | |
WO2022211177A1 (ko) | 인간 면역 글로불린 fc 및 목적단백질을 생산하는 조류의 제조방법 | |
EP3472198B1 (en) | Improved method for selecting polypeptide producing cells | |
KR20210081989A (ko) | 동물세포 발현벡터 | |
Kerry | Use of CHO cell synthetic promoters to control transcription of mAb expression vector genes and screening of ER genes for their effect on mAb production | |
Gadgil et al. | Cell Line Development for Biomanufacturing Processes | |
Becker | A combinatorial engineering approach to increase the productivity of CHO cells, and proteomic analysis of cell culture supernatant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080013851.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10758995 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13255004 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2010758995 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010758995 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6741/CHENP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012503316 Country of ref document: JP |